Furthermore, Mediresinol (MDN) activates PGC1α, promotes the interaction of PGC1α and PPARα in brain microvascular endothelial cells (BMECs), increases the expression of GOT1 and PAH, and ischemia-induced phenylalanine improves accumulation, thereby reducing mitochondrial ROS (mtROS). The gene discussed is PPARGC1A; the disease is pulmonary arterial hypertension.